Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer

Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · May 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying two different treatment combinations for patients with advanced colorectal cancer that has not responded to previous therapies. Specifically, it is comparing the effectiveness of a combination of trifluridine/tipiracil with regorafenib to the same medication paired with bevacizumab. The goal is to see which combination helps patients live longer without their cancer getting worse. Researchers will also look at how safe each treatment is and how they affect patients' quality of life.

To participate in this trial, patients need to be at least 18 years old and have a specific type of colorectal cancer that can’t be surgically removed. They should have already undergone certain treatments for their cancer and be in good overall health. Participants can expect to take oral medications and will be monitored regularly throughout the study. It’s important to note that certain health conditions or recent treatments may prevent someone from joining the trial. If you think you might be eligible, discussing this with your doctor could be a great first step.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Sign Informed Consent Form (ICF) must be obtained during the screening visit, prior to the performance of any study procedure；
• • 2. Male or female patient aged ≥18 years old;
• • 3. Has histologically confirmed unresectable adenocarcinoma of the colon or rectum (all other histological types are excluded);
• • 4. RAS status must have been previously determined (mutant or wild-type) based on local assessment of tumor biopsy;
• • 5. Prior treatment regimens for the treatment of advanced colorectal cancer must have included a fluoropyrimidine, irinotecan, oxaliplatin, an anti-VEGF monoclonal antibody and/or an anti-EGFR monoclonal antibody for RAS wildtype patients;
• • 6. Has measurable or non-measurable disease as defined by RECIST version 1.1;
• • 7. Is able to swallow oral tablets;
• • 8. Estimated life expectancy ≥12 weeks;
• • 9. ECOG PS 0-1；
• 10. Has adequate organ function as defined by the following laboratory values obtained within 7 days prior to randomization:
• • Absolute neutrophil count ≥1.5×109/L; Platelet count ≥75×109/L; Hemoglobin≥90g/L (7 days without transfusion); Creatinine clearance ≥60 mL/min, assessed using the Cockcroft \& Gault formula; Total serum bilirubin \<1.5×upper limit of normal (ULN) (unless Gilbert disease confirmed); Aspartate aminotransferase (AST; SGOT) and alanine aminotransferase (ALT; SGPT) ≤ 2.5×ULN (unless if liver function abnormalities are due to underlying liver metastasis, AST (SGOT) and ALT (SGPT) ≤ 5×ULN); Urine protein \<1+ on urinalysis or 24-hour urine protein \<1g; International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5×ULN (For patients receiving anti-coagulant therapy the adequate therapeutic levels of PT should be confirmed).
• • Female of childbearing potential must have been tested negative in a serum pregnancy test within 7 days prior to randomization; All patients must agree to use a highly effective method of birth control as well as their partners during the study and lasting at least 6 months after the last dose.
• Exclusion Criteria:
• • 1. Prior trifluridine/tipiracil or TKI regimens for the treatment of advanced colorectal cancer;
• • 2. Pregnancy, lactating female or possibility of becoming pregnant during the study;
• • 3. Patients currently receiving or having received anticancer therapies within 4 weeks prior to randomization;
• • 4. Has not recovered from clinically relevant non-hematologic CTCAE grade ≥ 3 toxicity of previous anticancer therapy prior to randomization (excluding alopecia, and skin pigmentation);
• • 5. Has symptomatic central nervous system metastases that are neurologically unstable or requiring increasing doses of steroids to control CNS disease;
• • 6. Has severe or uncontrolled active acute or chronic infection;
• • 7. Has active or history of interstitial lung disease and/or pneumonitis, or pulmonary hypertension;
• • 8. Has any clinically significant active hepatitis, including but not limited to Hepatitis B or Hepatitis C Virus infection;
• • 9. Known carriers of HIV antibodies;
• • 10. Confirmed uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 150 mm Hg and/or diastolic blood pressure ≥ 100 mm Hg) or uncontrolled or symptomatic arrhythmia;
• • 11. Deep arterial thromboembolic events including cerebrovascular accident or myocardial infarction within the last 6 months prior to randomization;
• • 12. Major surgery within 4 weeks prior to randomization (the surgical incision should be fully healed prior to study drug administration), or has not recovered from side effects of previous surgery, or patient that may require major surgery during the study;
• • 13. Prior radiotherapy if completed less than 2 weeks before randomization, except if provided as a short course for symptoms palliation only;
• • 14. Other clinically significant medical conditions; Other malignancies.